Unlock instant, AI-driven research and patent intelligence for your innovation.

Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors

A technology for preparing medicine and pharmacy, applied in the field of combination of AIDS treatment, broad-spectrum HIV protease inhibitor, and antiretroviral agent

Inactive Publication Date: 2011-06-15
TIBOTEC PHARMA
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] It is also important to find compounds with high potency against both the natural form and the various variants, since the pill dose will be reduced if therapeutic concentrations are kept to a minimum

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors
  • Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors
  • Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0223] Embodiment 1: the preparation of compound 29

[0224]

[0225] 1.56 g of intermediate a-3 (R 2 = H, R 4 =-CH 2 -CH 2 -NH-(2-pyridyl)), a mixture of 0.59 g of triethylamine and 50 ml of dichloromethane, then add 1.25 g of 2-(acetylamino)-6-benzothiazolesulfonyl chloride, and place the reaction mixture at room temperature Stir overnight. After washing with water, the organic layer was separated, dried and the solvent was evaporated. The resulting brown solid was redissolved in methanol at 70 °C, cooled and filtered to yield 1.9 g (75%) of intermediate a-4 (R 2 = H, R 4 =-CH 2 -CH 2 -NH-(2-pyridyl),-A-R 6 =H).

[0226] To 6 grams of intermediate a-4 in 50 milliliters of dichloromethane (R 2 = H, R 4 =-CH 2 -CH 2 -NH-(2-pyridyl),-A-R 6 =H) to the mixture was added 7.3 ml of trifluoroacetic acid. The reaction mixture was stirred at room temperature for 6 hours. Add additional dichloromethane and wash with NaHCO 3 Solution wash. The organic layer was dri...

Embodiment 2

[0228] Embodiment 2: the preparation of compound 31

[0229]

[0230] 540 mg of intermediate a-5 (R 2 = H, R 4 =-CH 2 -(2-pyridyl),-A-R 6 =H), a mixture of 135 mg tert-butanol, 192 mg EDC, 101 mg triethylamine in 5 ml dichloromethane was stirred overnight at room temperature. Then use Na 2 CO 3 solution and brine to wash the reaction mixture. The organic layer was separated, dried and the solvent was evaporated. The residue was purified by prep-HPLC to afford 184 mg (26%) of compound 31 . Mass spectral data: m / z=702 (M+H)

Embodiment 3

[0231] Embodiment 3: the preparation of compound 33

[0232]

[0233] 540 mg of intermediate a-5 (R 2 = H, R 4 =-CH 2 -(2-pyridyl),-A-R 6 =H), 271 mg 1-[[[[(3S,3aR,6aS)+(3R,3aS,6aR)-hexahydrofuroyl (furo)[2,3-b]furan-3-yl]oxy] A mixture of carbonyl]oxy]-2,5-pyrrolidinedione, 101 mg of triethylamine in 5 ml of dichloromethane was stirred at room temperature for 24 hours. Then use Na 2 CO 3 solution and brine to wash the reaction mixture. The organic layer was separated, dried and the solvent was evaporated. The residue was purified by preparative HPLC to afford 161 mg (23%) of compound 33. Mass spectral data: m / z = 696 (M+H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
shear viscosityaaaaaaaaaa
Login to View More

Abstract

The present invention concerns broad spectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors. The invention provides the following compounds. It further relates to their use as broadspectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. It also concerns combinations thereof with anotheranti-retroviral agent, and to their use in assays as reference compounds or as reagents.

Description

[0001] This application is a Chinese patent application (national application number is No. 02804982.9, a divisional application with international application number PCT / EP02 / 01788). technical field [0002] The present invention relates to 2-(substituted-amino)-benzothiazole sulfonamides, their use as aspartic protease inhibitors, in particular as broad-spectrum HIV protease inhibitors, their preparation and medicaments containing them Compositions and diagnostic kits. The present invention also relates to the combination of said 2-(substituted-amino)-benzothiazolesulfonamides with another antiretroviral agent. The invention also relates to their use in assays as reference compounds or reactants. Background technique [0003] As we all know, the virus that causes AIDS (AIDS) has many names, including T-lymphotropic virus III (HTLV-III), or lymphadenopathy-associated virus (LAV), or AIDS-related virus (ARV), or human immunodeficiency virus (HIV). Until now, two disti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D493/04C07D277/82C07D401/12C07D417/12A61K31/428A61P31/18A61K31/4439A61K31/496A61K31/5377A61P31/14A61P43/00
CPCC07D417/12C07D277/82A61P31/14A61P31/18A61P43/00C07D493/04
Inventor D·L·N·G·祖尔莱劳克斯P·T·B·P·维格林克D·格特曼W·G·费许伦S·文德维勒M·-P·德贝图内J·O·A·德克尔佩尔S·L·C·穆尔斯H·A·德科克M·C·J·弗茨
Owner TIBOTEC PHARMA